Contraindications
Severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; acute porphyria; SLE; infants ≤2 mth; pregnancy and lactation.
|
Special Precautions
Renal or hepatic impairment; history of allergy or asthma; AIDS; G6PD deficiency (at risk of haemolytic reactions); elderly; ensure adequate fluid intake to reduce risk of crystalluria. Discontinue if rash develops.
|
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, hypersensitivity reactions, SLE, serum sickness-like syndrome, liver necrosis and hepatomegaly, myocarditis, pulmonary eosinophilia and fibrosing alveolitis, vasculitis, hypoglycaemia, hypothyroidism, neurological reactions, jaundice and kernicterus in premature neonates. Pseudomembranous colitis.
Potentially Fatal: Blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis. |
C
D if administered near term.
|
Drug Interactions
Potentiates effects of oral anticoagulants, methotrexate, phenytoin. Increased risk of crystalluria with compounds that render the urine acidic. Increased risk of blood dyscrasias with clozapine. Increased risk of hypoglycaemia with tolbutamide.
|
CIMS Class
|
ATC Classification
B05CA04 - sulfamethizole ; Belongs to the class of antiinfectives used as irrigating solutions.
D06BA04 - sulfamethizole ; Belongs to the class of topical sulfonamides used in the treatment of dermatological diseases. S01AB01 - sulfamethizole ; Belongs to the class of antiinfectives, sulfonamides. Used in the treatment of eye infections. J01EB02 - sulfamethizole ; Belongs to the class of short-acting sulfonamides. Used in the systemic treatment of infections. |